| P50 | author | Aziz Zaanan | Q40860284 |
| P2093 | author name string | Simon Pernot | |
| | Julien Taïeb | |
| | Claire Gallois | |
| | Juliette Palle | |
| | Adrien Rochand | |
| P2860 | cites work | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| | Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells | Q27824846 |
| | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 |
| | Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 |
| | Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study | Q27853010 |
| | Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene | Q28286890 |
| | Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data | Q31044850 |
| | Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial | Q33429869 |
| | Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study | Q33440401 |
| | Role of epithelial-mesenchymal transition in gastric cancer initiation and progression | Q33594912 |
| | Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type | Q33779412 |
| | Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma | Q34051933 |
| | Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. | Q34554455 |
| | Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase | Q34720797 |
| | Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma | Q35145369 |
| | Circulating tumor cells (CTCs) detected by RT-PCR and its prognostic role in gastric cancer: a meta-analysis of published literature | Q35182266 |
| | Droplet digital PCR measurement of HER2 in patients with gastric cancer | Q35603664 |
| | Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients. | Q53232564 |
| | Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer. | Q53604901 |
| | Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. | Q53606400 |
| | 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). | Q53738984 |
| | DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. | Q54204362 |
| | Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. | Q54291995 |
| | Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. | Q54402875 |
| | Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. | Q54559293 |
| | [Efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen in the treatment of HER2-positive advanced gastric cancer]. | Q54565457 |
| | Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy. | Q54599560 |
| | Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion. | Q54979386 |
| | Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† | Q61867571 |
| | Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. | Q64938836 |
| | Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer | Q68290745 |
| | Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer | Q78386151 |
| | Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models | Q79218019 |
| | Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections | Q82547098 |
| | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial | Q89029141 |
| | Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO) | Q89051528 |
| | Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial | Q36299086 |
| | The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature | Q36317603 |
| | Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer | Q36782629 |
| | Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer. | Q37109776 |
| | Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience. | Q37131686 |
| | Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. | Q37141350 |
| | HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target | Q37149210 |
| | Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways | Q37425090 |
| | Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102). | Q37456450 |
| | Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study | Q37580446 |
| | Prognostic value of circulating tumor cells in advanced gastric cancer patients receiving chemotherapy | Q37701745 |
| | Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer | Q38637978 |
| | Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer | Q38743961 |
| | PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma | Q38752291 |
| | Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. | Q38936367 |
| | Involvement of microRNAs in HER2 signaling and trastuzumab treatment. | Q38979308 |
| | HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. | Q39106714 |
| | A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines | Q40873102 |
| | Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. | Q41285012 |
| | Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer | Q41595482 |
| | Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer | Q45287928 |
| | A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1203 (HERBIS-5). | Q46028271 |
| | Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study. | Q47100522 |
| | Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study | Q47678852 |
| | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Q47745009 |
| | miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer | Q48549971 |
| | Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer. | Q49710712 |
| | HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee | Q50036642 |
| | Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. | Q50058854 |
| | HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer | Q50064802 |
| | Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer. | Q50571860 |
| | Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients. | Q50642054 |
| | Phase II trial of dacomitinib in patients with HER2-positive gastric cancer. | Q50911124 |
| | HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric o | Q50962654 |
| | HER2-positive gastric cancer with paraaortic nodal metastasis successfully resected after chemotherapy with trastuzumab: a case report. | Q51162084 |
| | First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. | Q51170722 |
| | HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. | Q51541370 |
| | Dual silencing of EGFR and HER2 enhances the sensitivity of gastric cancer cells to gefitinib. | Q52594690 |
| | Role of circulating tumor DNA in the management of patients with colorectal cancer. | Q52600927 |
| | The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition. | Q52657273 |
| | HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study. | Q53010792 |
| P433 | issue | 4 | |
| P304 | page(s) | 401-415 | |
| P577 | publication date | 2020-03-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives | |
| P478 | volume | 80 | |